



ASX ANNOUNCEMENT

Lumos and BARDA Partnership - Investor Briefing Recording

MELBOURNE, Australia (16 October 2024) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite investors to watch an archived video recording of the Company’s BARDA Partnership investor briefing, which was held on Friday, 11 October 2024 at 10.30 am (AEDT).

The video recording can be accessed by using the following link:

<https://youtu.be/eK2HScgTPsQ>

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 (0) 423 139 163

Investor Contact:

Jane Lowe

Managing Director, IR Department

ir@lumosdiagnostics.com

+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205, Australia

+61 3 9087 1598